- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Novel Combination of Sintilimab and Bevacizumab Biosimilar IBI305 Shows Significant Survival Benefit in HCC
June 23, 2021
New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.
More Intense Daratumumab Induction Offers Better Responses in Ultra High–Risk Multiple Myeloma
June 23, 2021
Intensifying daratumumab induction therapy may improve responses to therapy in patients with ultra high-risk multiple myeloma or primary plasma cell leukemia, according to prospective study results.
The Standard of Care for EGFR Exon 20 Insertion+ Lung Cancer
June 23, 2021
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
Sintilimab Plus Chemotherapy Prolongs OS in Recurrent or Metastatic ESCC
June 23, 2021
Sintilimab injection in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival as frontline treatment of patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.
Experts Explore Landscape Advancements for Cancer Immunotherapy Month
June 23, 2021
As numerous approvals across cancer settings and emerging approaches are explored in clinical research, new findings presented at the 2021 American Society of Clinical Oncology Annual Meeting in June continue to encourage investigators.
Niraparib Makes an Impression in the Frontline Setting of Advanced Ovarian Cancer
June 23, 2021
In an interview with Targeted Oncology, Kathleen Moore, MD, discusses the effects of niraparib for ovarian cancer in the earlier-line setting in more detail and how she anticipates it will change clinical practice.
Update of VISION Trial Shows Continued Efficacy of Tepotinib in NSCLC
June 23, 2021
Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.
Novel IO Approaches Are in Development for PD-1/PD-L1–Resistant Merkel Cell Carcinoma
June 23, 2021
Newer immunotherapy approaches continue to be explored to treat patients with relapsed or refractory MCC after PD-1/ PD-L1 inhibition.
Key Takeaways for the Treatment of Unresectable HCC
June 23, 2021
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.
Future of Unresectable HCC Management
June 23, 2021
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
Phase 3 REFLECT Trial in Unresectable HCC
June 23, 2021
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
Frontline Treatment Options for Unresectable HCC
June 23, 2021
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.